Αποτελέσματα Αναζήτησης
25 Ιουλ 2024 · The total global economic burden of genital HSV infection was estimated to cost $35.3 billion in 2016 (genital HSV-2 infection: $31.2 billion and genital HSV-1 infection $4.0 billion).
5 Ιαν 2012 · In a study population that was representative of the general population of HSV-1– and HSV-2–seronegative women, the investigational vaccine was effective in preventing HSV-1 genital disease...
Cost for screening ranged from US$7–100, treatment ranged from US$0.53–35 for an episodic therapy, US$240–2580 yearly for suppressive therapy, while hospitalisation for neonatal care ranged from US$5321–32 683.
Among age-based vaccination outcomes reporting $/QALY, the percent of outcomes indicating a cost per QALY of ≤$100,000 was 100% for influenza, 100% for pneumococcal, 69% for human papillomavirus, 71% for herpes zoster, and 50% for tetanus-diphtheria-pertussis vaccinations. Conclusions:
Fifteen out of 25 studies concluded that ZVL was cost-effective compared with no vaccine at a vaccine price ranging between US$93 and US$236 per dose (2018 US$), 40% of which were published after 2014. All industry-funded studies favored the use of ZVL.
24 Απρ 2022 · A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals From Challenge With HSV-2. J Virol (2016) 90:562–74. doi: 10.1128/JVI.01845-15
3 Ιουν 2016 · A therapeutic HSV-2 vaccine could reduce genital inflammation if viral shedding is contained; alternatively, therapeutic vaccines could result in increased genital inflammation as additional T-cells traffic to the genital tract, theoretically further increasing the risk of acquiring HIV.
